BioMarin Pharmaceutical Inc.
BMRN
$52.88
$0.300.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -43.17% | -137.28% | -128.98% | 124.43% | 109.43% |
| Total Depreciation and Amortization | -25.64% | -44.77% | -2.73% | -29.85% | -19.31% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 4.46% | 141.07% | 357.01% | 61.87% | 57.11% |
| Change in Net Operating Assets | 143.19% | -97.29% | 204.46% | -136.21% | 14.16% |
| Cash from Operations | 26.52% | -46.32% | 66.46% | 56.00% | 271.28% |
| Capital Expenditure | -24.78% | -108.51% | -54.08% | 19.82% | 35.76% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6,607.86% | -101.80% | -851.21% | -95.97% | -196.65% |
| Cash from Investing | 2,669.33% | -155.56% | -1,948.42% | -113.92% | -98.36% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -14.19% | -99.85% | -73.80% | -- |
| Repurchase of Common Stock | 27.33% | 45.00% | 63.19% | 26.69% | 22.36% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -845.74% | -- | -- | -- |
| Cash from Financing | 2,196.93% | 10.42% | 99.57% | -136.50% | 9.38% |
| Foreign Exchange rate Adjustments | 199.58% | -51.32% | 125.47% | -192.82% | -173.48% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,561.70% | -76.97% | 112.23% | -26.71% | 1,403.17% |